Atai Therapeutics Inc. has identified 3-alkylamine indole compounds acting as 5-HT2A receptor agonists and reported to be potentially useful for the treatment of anxiety, eating and neurological disorders.
Miralinc Pharma Inc. has patented new heterocyclic selective histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of type 2 Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, among others.
Humanwell Pharmaceutical US Inc. has synthesized new sigma non-opioid intracellular receptor 1 (SIGMAR1) antagonists reported to be useful for the treatment of cancer, pain, psychosis and substance abuse and dependence.
Betta Pharmaceuticals Co. Ltd. has prepared and tested probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) inhibitors reported to be useful for the treatment of cancer.
Work at Dark Blue Therapeutics Ltd. has led to the identification of proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to a MLLT1- or MLLT3-targeting moiety through a linker.
Bayer Consumer Care AG has disclosed new tachykinin NK1 and NK3 receptor dual antagonists reported to be useful for the treatment of breast cancer, endometriosis, hidradenitis, hypertrichosis, osteoporosis, polycystic ovary syndrome, preeclampsia and benign prostatic hyperplasia, among others.
Aurigene Oncology Ltd. and Olema Pharmaceuticals Inc. have jointly patented acylsulfonamide histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to be useful for the treatment of cancer.
μ-Opioid receptor agonists have been described in a Miralogx LLC patent as potentially useful for anesthesia and sedation and the treatment of anxiety disorders, asthma, depression and pain.
Aquinnah Pharmaceuticals Inc. has identified new TAR DNA-binding protein 43 (TARDBP; TDP-43) aggregation and microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.
RSS